Progentos Therapeutics

Progentos is developing first-class compounds to induce endogenous oligodendrocyte progenitor cells to remyelinate axons in patients with multiple sclerosis and other demyelinating diseases. Combining expertise in chemistry, biology, and in vivo models, Progentos discovers and develops novel small-molecule drugs for tissue regeneration in patients with degenerative diseases.